Lebwohl M - Search Results

1

Secukinumab in plaque psoriasis--results of two phase 3 trials.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. Among authors: lebwohl m. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.

2

Psoriasis and stress.

Lebwohl M, Tan MH. Lebwohl M, et al. Lancet. 1998 Jan 10;351(9096):82. doi: 10.1016/S0140-6736(05)78153-8. Lancet. 1998. PMID: 9439490 No abstract available.

3

Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.

Lebwohl M, Ast E, Callen JP, Cullen SI, Hong SR, Kulp-Shorten CL, Lowe NJ, Phillips TJ, Rosen T, Wolf DI, Quell JM, Sefton J, Lue JC, Gibson JR, Chandraratna RA. Lebwohl M, et al. J Am Acad Dermatol. 1998 May;38(5 Pt 1):705-11. doi: 10.1016/s0190-9622(98)70594-8. J Am Acad Dermatol. 1998. PMID: 9591815 Clinical Trial.

4

Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris.

Lebwohl M, Elewski B, Eisen D, Savin RC. Lebwohl M, et al. Cutis. 2001 Mar;67(3):261-6. Cutis. 2001. PMID: 11270304 Clinical Trial.

5

Newly available treatments for psoriatic arthritis and their impact on skin psoriasis.

Galadari H, Fuchs B, Lebwohl M. Galadari H, et al. Among authors: lebwohl m. Int J Dermatol. 2003 Mar;42(3):231-7. doi: 10.1046/j.1365-4362.2003.01449.x. Int J Dermatol. 2003. PMID: 12653923 Review.

6

Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.

Freeman AK, Linowski GJ, Brady C, Lind L, Vanveldhuisen P, Singer G, Lebwohl M. Freeman AK, et al. Among authors: lebwohl m. J Am Acad Dermatol. 2003 Apr;48(4):564-8. doi: 10.1067/mjd.2003.169. J Am Acad Dermatol. 2003. PMID: 12664020 Clinical Trial.

7

Psoriasis.

Lebwohl M. Lebwohl M. Lancet. 2003 Apr 5;361(9364):1197-204. doi: 10.1016/S0140-6736(03)12954-6. Lancet. 2003. PMID: 12686053 Review.

8

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; Alefacept Clinical Study Group. Lebwohl M, et al. Arch Dermatol. 2003 Jun;139(6):719-27. doi: 10.1001/archderm.139.6.719. Arch Dermatol. 2003. PMID: 12810502 Clinical Trial.

9

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.

Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D; Efalizumab Study Group. Lebwohl M, et al. N Engl J Med. 2003 Nov 20;349(21):2004-13. doi: 10.1056/NEJMoa030002. N Engl J Med. 2003. PMID: 14627785 Free article. Clinical Trial.

10

Tacrolimus ointment is effective for facial and intertriginous psoriasis.

Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A; Tacrolimus Ointment Study Group. Lebwohl M, et al. J Am Acad Dermatol. 2004 Nov;51(5):723-30. doi: 10.1016/j.jaad.2004.07.011. J Am Acad Dermatol. 2004. PMID: 15523350 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

719 results

Search Page